检索范围:
排序: 展示方式:
PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives
Yumeng Wang, Guiling Li
《医学前沿(英文)》 2019年 第13卷 第4期 页码 438-450 doi: 10.1007/s11684-018-0674-4
关键词: PD-1 PD-L1 immune checkpoint blockade antibody immunotherapy cervical cancer
《医学前沿(英文)》 页码 878-888 doi: 10.1007/s11684-023-0993-y
关键词: uveal melanoma liver-directed therapy immune checkpoint blockade SIRT anti-PD-1 anti-CTLA-4
Zhen Xiang, Yingyan Yu
《医学前沿(英文)》 2019年 第13卷 第1期 页码 24-31 doi: 10.1007/s11684-019-0679-7
关键词: immune checkpoint blockade sensitivity resistance data mining
《医学前沿(英文)》 页码 805-822 doi: 10.1007/s11684-023-1025-7
关键词: CTLA-4 PD-1 PD-L1 immune checkpoint blockade (ICB) metabolic reprogramming combined tumor therapeutic strategies
Advances on immune-related adverse events associated with immune checkpoint inhibitors
Yong Fan, Yan Geng, Lin Shen, Zhuoli Zhang
《医学前沿(英文)》 2021年 第15卷 第1期 页码 33-42 doi: 10.1007/s11684-019-0735-3
关键词: cancer immunotherapy immune checkpoint inhibitors immune-related adverse events review
Molecular classification and precision therapy of cancer: immune checkpoint inhibitors
null
《医学前沿(英文)》 2018年 第12卷 第2期 页码 229-235 doi: 10.1007/s11684-017-0581-0
On May 23, 2017, the US Food and Drug Administration (FDA) approved a treatment for cancer patients with positive microsatellite instability-high (MSI-H) markers or mismatch repair deficient (dMMR) markers. This approach is the first approved tumor treatment using a common biomarker rather than specified tumor locations in the body. FDA previously approved Keytruda for treatment of several types of malignancies, such as metastatic melanoma, metastatic non-small-cell lung cancer, recurrent or metastatic head and neck cancer, refractory Hodgkin lymphoma, and urothelial carcinoma, all of which carry positive programmed death-1/programmed death-ligand 1 biomarkers. Therefore, indications of Keytruda significantly expanded. Several types of malignancies are disclosed by MSI-H status due to dMMR and characterized by increased neoantigen load, which elicits intense host immune response in tumor microenvironment, including portions of colorectal and gastric carcinomas. Currently, biomarker-based patient selection remains a challenge. Pathologists play important roles in evaluating histology and biomarker results and establishing detection methods. Taking gastric cancer as an example, its molecular classification is built on genome abnormalities, but it lacks acceptable clinical characteristics. Pathologists are expected to act as “genetic interpreters” or “genetic translators” and build a link between molecular subtypes with tumor histological features. Subsequently, by using their findings, oncologists will carry out targeted therapy based on molecular classification.
关键词: molecular classification precision medicine pembrolizumab PD-1/PD-L1 MSI-H
Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy
《医学前沿(英文)》 2022年 第16卷 第3期 页码 307-321 doi: 10.1007/s11684-022-0927-0
关键词: tumor immunotherapy immune checkpoint inhibitor antibiotics gut microbiota drug–drug interaction
《医学前沿(英文)》 2022年 第16卷 第5期 页码 773-783 doi: 10.1007/s11684-021-0902-1
关键词: benefit China eligibility immune checkpoint inhibitor public health
《医学前沿(英文)》 2022年 第16卷 第4期 页码 596-609 doi: 10.1007/s11684-021-0868-z
关键词: innate immune checkpoint Siglec10 kidney renal clear cell carcinoma
Development of oncolytic virotherapy: from genetic modification to combination therapy
Qiaoshuai Lan, Shuai Xia, Qian Wang, Wei Xu, Haiyan Huang, Shibo Jiang, Lu Lu
《医学前沿(英文)》 2020年 第14卷 第2期 页码 160-184 doi: 10.1007/s11684-020-0750-4
关键词: immunotherapy oncolytic virus genetic modification immune checkpoint blockade chimeric antigen receptor T cell
Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy
Min Zhang, Jingwen Yang, Wenjing Hua, Zhong Li, Zenghui Xu, Qijun Qian
《医学前沿(英文)》 2019年 第13卷 第1期 页码 32-44 doi: 10.1007/s11684-018-0678-0
Immunotherapy has become the fourth cancer therapy after surgery, chemotherapy, and radiotherapy. In particular, immune checkpoint inhibitors are proved to be unprecedentedly in increasing the overall survival rates of patients with refractory cancers, such as advanced melanoma, non-small cell lung cancer, and renal cell carcinoma. However, inhibitor therapies are only effective in a small proportion of patients with problems, such as side effects and high costs. Therefore, doctors urgently need reliable predictive biomarkers for checkpoint inhibitor therapies to choose the optimal therapies. Here, we review the biomarkers that can serve as potential predictors of the outcomes of immune checkpoint inhibitor treatment, including tumor-specific profiles and tumor microenvironment evaluation and other factors.
关键词: immune checkpoint companion diagnosis PD-L1 tumor mutation burden immune score
Activation of phagocytosis by immune checkpoint blockade
null
《医学前沿(英文)》 2018年 第12卷 第4期 页码 473-480 doi: 10.1007/s11684-018-0657-5
Inhibition of macrophage-mediated phagocytosis has emerged as an essential mechanism for tumor immune evasion. One mechanism inhibiting the innate response is the presence of the macrophage inhibitory molecule, signal regulatory protein-α (SIRPα), on tumor-associated macrophages (TAMs) and its cognate ligand cluster of differentiation 47 (CD47) on tumor cells in the tumor microenvironment. On the basis of a recently discovered programmed death protein 1 (PD-1) in TAMs, we discuss the potential inhibitory receptors that possess new functions beyond T cell exhaustion in this review. As more and more immune receptors are found to be expressed on TAMs, the corresponding therapies may also stimulate macrophages for phagocytosis and thereby provide extra anti-tumor benefits in cancer therapy. Therefore, identification of biomarkers and combinatorial therapeutic strategies, have the potential to improve the efficacy and safety profiles of current immunotherapies.
关键词: CD47 PD-1 PD-L1 immunotherapy TAM phagocytosis macrophage
CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer
《医学前沿(英文)》 2023年 第17卷 第1期 页码 105-118 doi: 10.1007/s11684-022-0934-1
关键词: osimertinib anti-CD47 antibody combination strategy ADCP EGFR
Immunometabolism: a new dimension in immunotherapy resistance
《医学前沿(英文)》 2023年 第17卷 第4期 页码 585-616 doi: 10.1007/s11684-023-1012-z
关键词: immune cell immunometabolism metabolic reprogramming immunotherapy resistance tumor microenvironment immune checkpoint inhibitor
《医学前沿(英文)》 doi: 10.1007/s11684-023-0996-8
标题 作者 时间 类型 操作
PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives
Yumeng Wang, Guiling Li
期刊论文
Liver-directed treatment is associated with improved survival and increased response to immune checkpointblockade in metastatic uveal melanoma: results from a retrospective multicenter trial
期刊论文
Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases
Zhen Xiang, Yingyan Yu
期刊论文
Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms
期刊论文
Advances on immune-related adverse events associated with immune checkpoint inhibitors
Yong Fan, Yan Geng, Lin Shen, Zhuoli Zhang
期刊论文
Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors
期刊论文
Innate immune checkpoint Siglec10 in cancers: mining of comprehensive omics data and validation in patient
期刊论文
Development of oncolytic virotherapy: from genetic modification to combination therapy
Qiaoshuai Lan, Shuai Xia, Qian Wang, Wei Xu, Haiyan Huang, Shibo Jiang, Lu Lu
期刊论文
Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy
Min Zhang, Jingwen Yang, Wenjing Hua, Zhong Li, Zenghui Xu, Qijun Qian
期刊论文